FDA Names Supervisory Medical Officer Kathleen Uhl as Office of Women ‘s Health Directoris FDA on Monday expected to Kathleen Uhl, a veteran agency official who last served as supervisory authority medical officer in FDA Center for Drug Evaluation and Research as director of call of Office of women’s Health, the Washington Post reports (Kaufman, Washington Post, Uhl replaced Susan Wood, who in September to move by the agency to protest its action indefinitely a decision on Barr Laboratories ‘ application for nonprescription sales of its emergency contraceptive resigned plan as a biologist, was to serve as an assistant FDA commissioner for women’s health serving since 2000. Theresa Toigo, director of the agency ‘s Office of Special Health Issues, currently deputy director of women’s health get information . Toigo was appointed shortly after Agency sent an e – mail alert to women’s groups and others announcing the appointment to the post of Norris Alderson, associate Commissioner of the Agency for Science , who has spent much of his career, at the FDA Center for Veterinary Medicine (Kaiser Daily Reproductive Health Report, Several groups Alderson nomination and later the Agency protesting known that Toigo had been selected. According to the draft FDA release Uhl began working as medical advisors to the FDA in 1998 and was later appointed deputy director and acting head of the Office of Post-Marketing drug Risk Assessment. Uhl in laboratory and clinical research, clinical practice, drug application review work drug safety oversight and women’s health. She is also a practicing physician at the Walter Reed said Army Medical Center in Washington, DC wood Uhl would be a good choice for the job, adding often often with Uhl and that she is a longtime advocate for women’s health in position agency. Uhl, the takeover the position in December (Washington Post.
courtesy of you, the entire Kaiser Daily Health Policy Report indicate J.earch the archives, or sign up for email delivery at Kaiser Daily Health Policy Report strongly supports kaiser network. A free service of The Henry J. Released. Kaiser Family Foundation. 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
The patients of the torcetrapib / atorvastatin group underwent a 61 % the relative increase in HDL cholesterol levels, and 20 per cent relative decrease in the LDL level, as patients in of atorvastatin-only group compared. Despite these findings, there between both groups between the two groups at plaque volume changes. Plaques volumetric by 0.19 % in the atorvastatin-only patient and 0.12 % in the combination group, increases seventy second Torcetrapib is connected with a significant rise in blood pressure. During the study, the torcetrapib torcetrapib average standing systolic blood pressure, 6 mmHg higher than the of atorvastatin patient only. Beyond both torcetrapib patients twice as common twice as likely for increasing the systolic BP more than 15mmHg as compared atorvastatin alone. In Hall A. Please torcetrapib / atorvastatin combining considerably increasing well cholesterol level and reduces bad cholesterol Yet of this drug significantly blood pressure, an unwanted effect increases, and does not slowing down the buildup of plaque, ‘said Steven portraits, to the Cleveland Clinic and lead author of the trial. Nep is well President American College of Cardiology. ‘Whether this error represents be a problem is unique torcetrapib or proposing a a lack of efficacy the entire Class on like medicines yet be determined. Our results indicate the extreme difficulty in developing therapies which the atherosclerosis. Twenty years after the launch statins, We are still for the next breakthrough. ‘.